Crestor dons chef's hat with online cooking show series

Share this article:
Crestor dons chef's hat with online cooking show series
Crestor dons chef's hat with online cooking show series
AstraZeneca is launching an online campaign to promote a healthy diet as part of its Crestor efforts.

The company is partnering with cooking site Food University on the effort, which features Food Network chef Sara Moulton and chef Curtis Aikens. The duo appear in a series of short online cooking videos that will appear on Crestor.com as well as MyFoodU.com.

At the beginning of the videos, “AstraZeneca Pharmaceuticals, the makers of Crestor,” is credited as a sponsor.

AstraZeneca's Stephanie Jacobson, director of brand corporate affairs, said in a statement that the company had partnered with Food University “to educate people about the importance of maintaining a healthy diet as one way to help manage cholesterol” and to “empower people to take control of their health by showing how even small changes, like incorporating more low-cholesterol foods into their diet, can make a difference.”

Jacobson noted American Heart Association figures estimating that only 17% of Americans 60 and over eats a quality diet.

Other Food University sponsors include Classico, FamilyCircle and Ikea, which is hosting a series of live events in different cities around the country.
Share this article:

Email Newsletters

More in News

Survey finds pay doesn't make doctors happy

Survey finds pay doesn't make doctors happy

Medscape's survey of over 24,000 physicians found that a paycheck is not necessarily linked to a physician's professional satisfaction.

CDC sees declines in some diabetes complications

CDC sees declines in some diabetes complications

Centers for Disease Control data shows that diabetes complications including heart attack and amputation fell in the twenty years between 1990 and 2010. The bad news: the number of diagnosed ...

BI rethinks hepatitis business, posts 2013 results

BI rethinks hepatitis business, posts 2013 results

Boehringer Ingelheim says it is no longer pursuing an interferon-free combination of faldaprevir and deleobuvir.